Tucatinib
- Generic Name
- Tucatinib
- Brand Names
- Tukysa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N8O2
- CAS Number
- 937263-43-9
- Unique Ingredient Identifier
- 234248D0HH
- Background
Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other ch...
- Indication
本品与曲妥珠单抗和卡培他滨联用治疗人类表皮生长因子受体2(HER2)阳性且已出现转移(如脑转移)或无法进行乳房切除术的乳腺癌成人患者，患者应接受过一种或多种抗HER2乳腺癌药物治疗。
- Associated Conditions
- Breast Cancer, Unresectable Breast Cancer, Wild-type RAS Metastatic Colorectal Cancer, Unresectable RAS Wild Type Colorectal Cancer
- Associated Therapies
- -
A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03758339
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03723395
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03722823
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 17
- Registration Number
- NCT03501979
- Locations
- 🇺🇸
University of Michigan-, Ann Arbor, Michigan, United States
🇺🇸UCSF-Mission Bay, San Francisco, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT03424473
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 720
- Registration Number
- NCT03297606
- Locations
- 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦BCCA - Kelowna, Kelowna, British Columbia, Canada
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT03043313
- Locations
- 🇺🇸
Texas Oncology - Beaumont, Beaumont, Texas, United States
🇺🇸Lombardi Cancer Center / Georgetown University Medical Center, Washington, District of Columbia, United States
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Other, Spain
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 279
- Registration Number
- NCT02892123
- Locations
- 🇺🇸
Hoag Family Cancer Institute, Newport Beach, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT02614794
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Paris Regional Medical Center / US Oncology, Paris, Texas, United States
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02025192
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.